Cover Image
市場調查報告書

癌症CD抗原抑制劑的市場與開發平台分析 (2015年)

Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 338400
出版日期 內容資訊 英文 600 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症CD抗原抑制劑的市場與開發平台分析 (2015年) Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015
出版日期: 2015年08月27日 內容資訊: 英文 600 Pages
簡介

全球各國的製藥企業,現在進行癌症的CD (表面抗原) 用抑制劑臨床實驗,其中幾個已上市。製造成本高是目前的挑戰,不過,預期今後的研究開發的發展,其問題也總會解決。

本報告提供癌症治療用的CD抗原抑制劑臨床實驗情形相關分析、CD抗原的概要,及整體產品開發情形、抗原的詳細臨床實驗進展、已上市產品狀況等調查、考察、主要企業簡介等資訊彙整,為您概述為以下內容。

第1章 CD抗原的概要

第2章 CD抗原的分類

第3章 CD抗原癌症治療藥的機制

第4章 癌症CD抗原療法的市場概要

  • 目前方案
  • 癌症CD抗原抑制劑的開發中產品的概要

第5章 CD抗原癌症市場趨勢

  • 良好的市場指標
  • 商業化時的課題

第6章 CD抗原癌症治療藥的未來展望

第7章 癌症CD抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一/二階段

第8章 癌症CD3抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第二階段

第9章 癌症CD4抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第二階段

第10章 癌症CD9抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床

第11章 癌症CD11抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床

第12章 癌症CD19抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段∼第二階段

第13章 癌症CD20抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 研究階段∼第三階段
  • 已上市產品相關的臨床實驗上的考察

第14章 癌症CD22抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第二階段∼第三階段

第15章 癌症CD26抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第一/二階段

第16章 癌症CD27抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 研究階段∼第一/二階段

第17章 癌症CD28抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床

第18章 癌症CD29抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床

第19章 癌症CD33抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段∼第一/二階段
  • 已上市產品相關的臨床實驗上的考察

第20章 癌症CD37抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段∼第二階段

第21章 癌症CD38抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 研究階段∼登記前

第22章 癌症CD40抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段

第23章 癌症CD44抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床

第24章 癌症CD45抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第二階段

第25章 癌症CD47抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第一階段

第26章 癌症CD52抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 研究階段∼前臨床
  • 已上市產品相關的臨床實驗上的考察

第27章 癌症CD55抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第二階段

第28章 癌症CD56抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第二階段

第29章 癌症CD66抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第二階段

第30章 癌症CD70抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段

第31章 癌症CD74抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第一/二階段

第32章 癌症CD80抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第二階段

第33章 癌症CD95抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床

第34章 癌症CD98抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段

第35章 癌症CD100抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段

第36章 癌症CD117抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第三階段
  • 已上市產品相關的臨床實驗上的考察

第37章 癌症CD135抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第三階段
  • 已上市產品相關的臨床實驗上的考察

第38章 癌症CD137抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床

第39章 癌症CD152抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 已上市產品相關的臨床實驗上的考察

第40章 癌症CD200抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床

第41章 癌症CD223抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 研究階段∼第一階段

第42章 癌症CD227抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段∼第二階段

第43章 癌症CD246抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第二階段
  • 已上市產品相關的臨床實驗上的考察

第44章 癌症CD248抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第二階段

第45章 癌症CD274抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 研究階段∼第三階段
  • 已上市產品相關的臨床實驗上的考察

第46章 癌症CD276抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段

第47章 癌症CD279抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 第一階段∼第二階段
  • 已上市產品相關的臨床實驗上的考察

第48章 複數的癌症CD抗原抑制劑臨床實驗開發平台:各企業、各適應症、各階段

  • 前臨床∼第三階段
  • 已上市產品相關的臨床實驗上的考察

第49章 中止、延期的臨床實驗相關考察:癌症CD抗原抑制劑的情況

  • 臨床實驗報告沒被發出的東西
  • 臨床實驗中止的東西
  • 從市場退出的東西
  • 臨床實驗被中斷的東西

第50章 競爭環境

  • Alexion Pharmaceuticals
  • ARIAD Pharmaceuticals
  • AryoGen Biopharma
  • AXXO
  • Bayer HealthCare
  • Biocad
  • Biogen
  • Biotecnol Inc.
  • Bristol-Myers Squibb
  • 中外製藥
  • Dr Reddy's Laboratories
  • Eisai
  • Emergent BioSolutions
  • Genmab
  • ImmunoGen
  • Intas Biopharmaceuticals
  • MacroGenics
  • MedImmune
  • Merck
  • Novartis
  • 小野藥品工業
  • Onyx Pharmaceuticals
  • Pfizer
  • PROBIOMED
  • Roche
  • UCB
  • Xencor

圖表一覽

目錄

Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Several options for cancer treatment are available belonging to various classes of molecules. Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment. Several molecules have been discovered out of which CD antigens have been found to play an important role in cancer progression and proliferation. Investigators are trying to assign different functions to CD antigens by doing extensive research and development. Their role in cancer development has been noted due to which lots of progress would be observed in this segment. Most of the work has been done in cancer segment and pharmacological profiles are expected to be improved in coming years.

CD antigen cancer therapeutics have diverse design and target due to which they could be used for several malignancies. Presence of BiTEs, ADC, monoclonal antibodies and tri-functional antibodies for targeting different CD antigens has been commercialized. Next step is assumed to be the improvement in design as complexity at molecular levels makes it difficult to manufacture them in large quantities. This issue not only decreases the productivity but also increases the cost of production. Higher cost of end products limits the number of cancer patients choosing them as a part of their regular therapeutic regime. With the use of advanced technology it is expected that this issue would be overcome in coming years. Some of the progress could be observed in case of monoclonal antibodies and same scenario could be observed for other CD antigen cancer therapeutics in coming years.

Clinical trials are being instigated across the globe in order to extend their utilities in different malignancies. They are versatile in nature due to which they could be used as a part of combinatorial therapy along with monoclonal antibodies. Their utilities in different malignancies are also being studied but results of such clinical trials remains elusive. They have strong clinical pipeline due to which several products would be introduced in coming years. However, these products are at different stages of clinical pipeline and they may take long winding times as lots of experiments proving their safety and efficacy has to be done. With time more CD antigens are expected to be discovered and they would help in the increased market size. Commercial success of marketed CD antigen cancer therapeutics shows that they would be generating significant revenues in coming years.

CD antigen cancer market is expected to witness introduction of several products which will help the pharmaceutical companies to generate significant revenues. Increasing demand for better therapeutics, large unmet medical necessities and large numbers of cancer patient's patient are expected to be responsible for the growth of this market segment. Increased funding in research and development along with utilization of advanced technology will also help in increasing their market shares across the globe. Numerous innovative CD antigen cancer therapeutics are at different stages of clinical trials which would increase their market shares. Despite these facts they have higher prices and their manufacturing is difficult but utilization of advanced technology along with streamlining of various processes are expected to overcome this barrier. In this way, future of CD antigen cancer therapeutics looks optimistic due to their superior pharmacological profiles.

CD Antigens Segments in Report:

CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52, CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279

"Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015" Report Highlight:

  • Nomenclature & Classification of CD Antigens
  • Mechanism of CD Antigen Cancer Therapeutics
  • Cancer CD Antigen Therapy Market Overview
  • Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs
  • Marketed Cancer CD Antigen Inhibitors: 27 Drugs
  • Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs
  • Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs
  • Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts

Table of Contents

1. Introduction to CD Antigens

2. Nomenclature & Classification of CD Antigens

3. Mechanism of CD Antigen Cancer Therapeutics

4. Cancer CD Antigen Therapy Market Overview

  • 4.1 Current Scenario
  • 4.2 Cancer CD Antigen Inhibitors Pipeline Overview

5. CD Antigen Cancer Market Dynamics

  • 5.1 Favorable Market Parameters
  • 5.2 Commercialization Challenges

6. CD Antigen Cancer Therapeutics Future Prospects

7. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 7.1 Phase-I/II

8. Cancer CD3 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 8.1 Preclinical till Phase-II

9. Cancer CD4 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 9.1 Phase-II

10. Cancer CD9 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 10.1 Preclinical

11. Cancer CD11 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 11.1 Preclinical

12. Cancer CD19 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 12.1 Phase-I till Phase-II

13. Cancer CD20 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 13.1 Research till Phase-III
  • 13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight

14. Cancer CD22 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 14.1 Phase-II till Phase-III

15. Cancer CD26 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 15.1 Preclinical till Phase-I/II

16. Cancer CD27 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 16.1 Research till Phase-I/II

17. Cancer CD28 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 17.1 Preclinical

18. Cancer CD29 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 18.1 Preclinical

19. Cancer CD33 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 19.1 Phase-I till Phase-I/II
  • 19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight

20. Cancer CD37 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 20.1 Phase-I till Phase-II

21. Cancer CD38 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 21.1 Research till Preregistration

22. Cancer CD40 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 22.1 Phase-I

23. Cancer CD44 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 23.1 Preclinical

24. Cancer CD45 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 24.1 Preclinical till Phase-II

25. Cancer CD47 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 25.1 Preclinical till Phase-I

26. Cancer CD52 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 26.1 Research till Preclinical
  • 26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight

27. Cancer CD55 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 27.1 Preclinical till Phase-II

28. Cancer CD56 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 28.1 Preclinical till Phase-II

29. Cancer CD66 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 29.1 Preclinical till Phase-II

30. Cancer CD70 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 30.1 Phase-I

31. Cancer CD74 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 31.1 Preclinical till Phase-I/II

32. Cancer CD80 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 32.1 Preclinical till Phase-II

33. Cancer CD95 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 33.1 Preclinical

34. Cancer CD98 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 34.1 Phase-I

35. Cancer CD100 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 35.1 Phase-I

36. Cancer CD117 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 36.1 Preclinical till Phase-III
  • 36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight

37. Cancer CD135 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 37.1 Preclinical till Phase-III
  • 37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight

38. Cancer CD137 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 38.1 Preclinical

39. Cancer CD152 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight

40. Cancer CD200 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 40.1 Preclinical

41. Cancer CD223 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 41.1 Research till Phase-I

42. Cancer CD227 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 42.1 Phase-I till Phase-II

43. Cancer CD246 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 43.1 Preclinical till Phase-II
  • 43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight

44. Cancer CD248 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 44.1 Phase-II

45. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 45.1 Research till Phase-III
  • 45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight

46. Cancer CD276 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 46.1 Phase-I

47. Cancer CD279 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 47.1 Phase-I till Phase-II
  • 47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight

48. Multiple Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 48.1 Preclinical till Phase-III
  • 48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight

49. Discontinued & Suspended Cancer CD Antigen Inhibitors Drug Clinical Insight

  • 49.1 No Development Reported
  • 49.2 Discontinued
  • 49.3 Market Withdrawal
  • 49.4 Suspended

50. Competitive Landscape

  • 50.1 Alexion Pharmaceuticals
  • 50.2 ARIAD Pharmaceuticals
  • 50.3 AryoGen Biopharma
  • 50.4 AXXO
  • 50.5 Bayer HealthCare
  • 50.6 Biocad
  • 50.7 Biogen
  • 50.8 Biotecnol Inc.
  • 50.9 Bristol-Myers Squibb
  • 50.10 Chugai Pharmaceutical
  • 50.11 Dr Reddy's Laboratories
  • 50.12 Eisai Co Ltd
  • 50.13 Emergent BioSolutions
  • 50.14 Genmab
  • 50.15 ImmunoGen
  • 50.16 Intas Biopharmaceuticals
  • 50.17 MacroGenics
  • 50.18 MedImmune
  • 50.19 Merck
  • 50.20 Novartis
  • 50.21 Ono Pharmaceutical
  • 50.22 Onyx Pharmaceuticals
  • 50.23 Pfizer
  • 50.24 PROBIOMED
  • 50.25 Roche
  • 50.26 UCB
  • 50.27 Xencor

List of Figures

  • Figure 1-1: Functions of CD Antigens
  • Figure 1-2: Properties of CD Antigens
  • Figure 2-1: Types of WBC
  • Figure 2-2: Classification of CD Antigens
  • Figure 3-1: Important Features of CD Antigens
  • Figure 3-2: Mechanism of Rituximab
  • Figure 3-3: Mechanism of Brentuximab Vedotin
  • Figure 3-4: Mechanism of Blinatumomab
  • Figure 3-5: Mechanism of Ibritumomab Tiuxetan
  • Figure 3-6: Mechanism of Tositumomab Iodine 131
  • Figure 3-7: Mechanism of Catumaxomab
  • Figure 4-1: Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-2: Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-3: Cancer CD3 Antigen Pipeline by Phase (%), 2015
  • Figure 4-4: Cancer CD3 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-5: Cancer CD19 Antigen Pipeline by Phase (%), 2015
  • Figure 4-6: Cancer CD19 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-7: Cancer CD20 Antigen Pipeline by Phase (%), 2015
  • Figure 4-8: Cancer CD20 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-9: Cancer CD22 Antigen Pipeline by Phase (%), 2015
  • Figure 4-10: Cancer CD22 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-11: Cancer CD26 Antigen Pipeline by Phase (%), 2015
  • Figure 4-12: Cancer CD26 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-13: Cancer CD27 Antigen Pipeline by Phase (%), 2015
  • Figure 4-14: Cancer CD27 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-15: Cancer CD33 Antigen Pipeline by Phase (%), 2015
  • Figure 4-16: Cancer CD33 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-17: Cancer CD38 Antigen Pipeline by Phase (%), 2015
  • Figure 4-18: Cancer CD38 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-19: Cancer CD45 Antigen Pipeline by Phase (%), 2015
  • Figure 4-20: Cancer CD45 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-21: Cancer CD47 Antigen Pipeline by Phase (%), 2015
  • Figure 4-22: Cancer CD47 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-23: Cancer CD52 Antigen Pipeline by Phase (%), 2015
  • Figure 4-24: Cancer CD52 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-25: Cancer CD55 Antigen Pipeline by Phase (%), 2015
  • Figure 4-26: Cancer CD55 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-27: Cancer CD56 Antigen Pipeline by Phase (%), 2015
  • Figure 4-28: Cancer CD56 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-29: Cancer CD66 Antigen Pipeline by Phase (%), 2015
  • Figure 4-30: Cancer CD66 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-31: Cancer CD74 Antigen Pipeline by Phase (%), 2015
  • Figure 4-32: Cancer CD74 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-33: Cancer CD80 Antigen Pipeline by Phase (%), 2015
  • Figure 4-34: Cancer CD80 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-35: Cancer CD117 Antigen Pipeline by Phase (%), 2015
  • Figure 4-36: Cancer CD117 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-37: Cancer CD135 Antigen Pipeline by Phase (%), 2015
  • Figure 4-38: Cancer CD135 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-39: Cancer CD223 Antigen Pipeline by Phase (%), 2015
  • Figure 4-40: Cancer CD223 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-41: Cancer CD227 Antigen Pipeline by Phase (%), 2015
  • Figure 4-42: Cancer CD227 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-43: Cancer CD246 Antigen Pipeline by Phase (%), 2015
  • Figure 4-44: Cancer CD246 Antigen Pipeline by Phase (Number), 2015
  • Figure 4-45: Multiple Cancer CD Antigen Pipeline by Phase (%), 2015
  • Figure 4-46: Multiple Cancer CD Antigen Pipeline by Phase (Number), 2015
  • Figure 4-47: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (%), 2015
  • Figure 4-48: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (Number), 2015
  • Figure 4-49: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (%), 2015
  • Figure 4-50: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (Number), 2015
  • Figure 4-51: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (%), 2015
  • Figure 4-52: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (Number), 2015
  • Figure 5-1: Favorable Market Features
  • Figure 5-2: Cancer CD Antigen Inhibitors Commercialization Challenges
  • List of Tables
  • Table 5-1: Different CD Antigens used for Hematological Malignancies
Back to Top